Daclizumab as induction therapy in kidney and simultaneous pancreas-kidney transplantation

G. Ciancio*, A. Mattiazzi, J. Miller, G. W. Burke

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Acute rejection still remains a major problem in organ transplantation and is a significant risk factor for chronic rejection, and chronic rejection is one of the most important causes of late graft loss. Current new immunosuppressive drugs such as tacrolimus, rapamycin and mycophenolate mofetil have been developed to reduce acute rejection and to improve renal allograft survival. More recently, antihuman antibodies, either monoclonal or polyclonal, have been developed to use for induction therapy at the time of transplantation or to treat rejection. Daclizumab, a new engineered human immunoglobulin monoclonal antibody to the interleukin-2 receptor α-subunit was approved to prevent acute rejection after solid organ transplantation. Data from clinical trials show daclizumab to be well tolerated in solid organ transplantation. It does not increase the incidence of infection, including cytomegalovirus infection.

Original languageEnglish (US)
Pages (from-to)43-56
Number of pages14
JournalMinerva Urologica e Nefrologica
Issue number1
StatePublished - Mar 1 2003


  • Graft rejection
  • Immunosuppressive agents
  • Kidney transplantation

ASJC Scopus subject areas

  • Nephrology
  • Urology


Dive into the research topics of 'Daclizumab as induction therapy in kidney and simultaneous pancreas-kidney transplantation'. Together they form a unique fingerprint.

Cite this